| INTRODUCTIONHuman hepatocellular carcinoma(HCC) is one of the major causes of death worldwide, and surgical resection is the only curative therapy. However it has limitations for patients with multiple type or metastatic tumors. HCC is usually insensitive to chemotherapeutic drugs currently used in clinical setting.Searching for effective chemotherapeutic agents is important to improve the survival rate of patients with advanced or recurrent HCC , and there is thus an urgent need for the evaluation of new active drugs against HCC.Docetaxel is a new taxoid structurally similar to paclitaxel, a semisynthetic product of a renewable resource, the needles of the European yew, Taxus baccata L. In comparison to paclitaxel,docetaxel is more potent as an inhibitor of microtubule depolymerization. Docetaxel has shown an active effect against cancers. Docetaxel has been used in the treatment of many carcinomas, including mammary cancer, NSCLC, pancreatic cancer, soft tissue sarcoma, head and neck cancer, stomach cancer, ovary cancer, prostate cancer, etc. It's antitumor activity is remarkable either in monotherapy or in combination therapy.Proteomics has been widespreadly implanted into every field of life science and medicine as an important part of post-genomics era research.The development of theory and technology in proteomics has provided new ideas and research fields for cancer research. Proteomics can be used for not only elucidating the mechanism of carcinogenesis from the whole proteins of the tissue or cell but also seeking the biomarkers for diagnosis and therapy of cancer.High-throughput proteomic profiling and bioinformatics tools allow for examining global changes in protein expression of hepatocellular carcinoma in response to docetaxel. Identification of differentialy expressed proteins may lead to a better understanding of the molecular events involved in docetaxel anti-hepatocellular carcinoma mechanism. Discovery of docetaxel-associated specific proteins may help to monitor...
|
PDF Full Text Request